Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Serial BioPharma Entrepreneurial Team launches drug development firm Arrivo BioVentures Serial BioPharma Entrepreneurial Team has launched Arrivo BioVentures, a drug development company, with $49m in committed funding.
Drug Research > Drug Discovery & Development > News
Allied-Bristol Life Sciences completes ABLS II drug candidate feasibility programme Allied-Bristol Life Sciences (ABLS), its partnership with Bristol-Myers Squibb Company (BMS), has completed the drug candidate feasibility programme at ABLS II, LLC (ABLS II), and approved up to $15m to fund further development of the lead optimisation programme.
Drug Research > Drug Discovery & Development > News Redx Pharma reaches pre-clinical proof of concept stage with oncology lead Redx Pharma has reached pre-clinical proof of concept stage with an oncology lead that has the potential to treat leukaemia and other blood cancers.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Boehringer Ingelheim, BioMed X start project to identify new treatment approaches for psychiatric diseases
By PBR Staff Writer
Boehringer Ingelheim and BioMed X have started a new project to identify and develop novel treatment approaches for psychiatric diseases.
Drug Research > Drug Discovery & Development > News
Avalon Ventures, COI form PDI Therapeutics to develop novel immune-oncology therapies
By PBR Staff Writer
Avalon Ventures and COI Pharmaceuticals have established PDI Therapeutics to develop novel immune-oncology therapies.
Drug Research > Drug Discovery & Development > News
Acorda to stop Plumiaz development to treat epilepsy seizure clusters
By PBR Staff Writer
Acorda Therapeutics said it will stop the development of its Plumiaz (diazepam) Nasal Spray for the treatment of epilepsy seizure clusters due to disappointing data from ongoing clinical trials.
Drug Research > Drug Discovery & Development > News
Amgen researchers discover gene variation that lowers heart attack risk
By PBR Staff Writer
Researchers from Amgen's deCODE genetics subsidiary have discovered a rare genetic variation that reduces cholesterol levels and heart attack risk in some people.
Drug Research > Drug Discovery & Development > News
Mitochon Pharmaceuticals raises $1.6m for clinical stage development
Mitochon Pharmaceuticals has completed its second year of funding with a total investment of $1.6m.
Drug Research > Drug Discovery & Development > News
Catalyst Pharmaceuticals announces 30% reduction in workforce
Catalyst Pharmaceuticals, which is focused on developing and commercializing new therapies for people with rare debilitating diseases, is reducing its workforce by approximately 30%.
Drug Research > Drug Discovery & Development > News
Agios, Celgene agree to establish metabolic immuno-oncology alliance
By CBR Staff Writer
Agios Pharmaceuticals and Celgene have signed an agreement to establish a new global collaboration focused on metabolic immuno-oncology.
Drug Research > Drug Discovery & Development > News
Pfizer to buy Anacor Pharmaceuticals in $5.2bn deal
By PBR Staff Writer
Pfizer has agreed to acquire Anacor Pharmaceuticals in a transaction valued at about $5.2bn.
Drug Research > Drug Discovery & Development > News
Five Prime advances FPA008 into phase 2 dose expansion in PVNS patients
Five Prime Therapeutics has advanced FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS.
Drug Research > Drug Discovery & Development > News
Aegerion reaches preliminary agreements in principle with DOJ and SEC over ongoing investigations
Aegerion Pharmaceuticals has reached preliminary agreements in principle with the Department of Justice (DOJ) and the staff of the Securities and Exchange Commission (SEC) regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID (lomitapide) capsules ("JUXTAPID").
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests